Fusion Pharmaceuticals
fusion strategy around combination therapies | Fusion Pharmaceuticals
Company
Deck Type
Sector
Industry
Deck date
August 2023
Slide
21 of 33
Similar slides by Fusion Pharmaceuticals
See diffirences between slides (animation)
Investor Presentation
November 2023
fusion strategy around combination therapies | Fusion Pharmaceuticals
Related slides by other companies
Alkermes
Investor Day
March 2021
enhanced the anti tumor efficacy of in mouse tumors tumor growth inhibition overall survival combination with growth factor pathway inhibitors days vehicle complete responses days in combination with either or not shown resulted in enhanced tumor suppression and survival relative to groups similar results observed with a mouse surrogate of which is a selective inhibitor of the angiogenesis factor alkermes internal data on file the mouse of was used in mouse tumor model | Alkermes
Alkermes
Investor Day
March 2021
in combination with growth factor pathway inhibitors enhanced cancer fighting mechanisms in mouse tumors combination with growth factor pathway inhibitors cells in tumor cells in tumor dendritic cells in tumor dendritic cells in tumor in tumor in tumor macrophages in tumor macrophages in tumor vehicle in combination with either or not shown resulted in increased immune activation and decreased immune suppression in tumors alkermes internal data on file the mouse of was used in mouse tumor model a a | Alkermes
Arbutus Biopharma
Investor Presentation
January 2024
small molecule oral inhibitor for | Arbutus Biopharma
Alkermes
Results
June 2021
artistry in combination with unapproved tumor types | Alkermes
Other recent decks by Fusion Pharmaceuticals
See all presentations (4 decks)
Investor Presentation
January 2024
Investor Presentation
November 2023
IPO
June 2020
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights